ETF Evaluator:
Invesco Biotechnology & Genome ETF (PBE)
Follow This ETF
(as of Jul 31)
Best Performing in Health Over the Last Year
| 177.8% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 114.6% | ALPS Medical Breakthroughs ETF (SBIO) |
| 91.7% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 83.9% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 79.5% | iShares Neuroscience and Healthcare ETF (IBRN) |
Risk
Index
Risk
Index
ETF Details
Invesco Biotechnology & Genome ETF Overview
Invesco Biotechnology & Genome ETF (PBE) is a passively managed Sector Equity Health exchange-traded fund (ETF). Invesco launched the ETF in 2005.
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index.
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
About Invesco Biotechnology & Genome ETF (PBE)
There are 3 members of the management team with an average tenure of 14.26 years: Peter Hubbard (2007), Michael Jeanette (2008) and Pratik Doshi (2020). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and Dynamic Biotech&Genome Intellidex TR USD index with a weighting of 100%. Invesco Biotechnology & Genome ETF has 32 securities in its portfolio. The top 10 holdings constitute 44.5% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Invesco Biotechnology & Genome ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Invesco Biotechnology & Genome ETF has 0.0% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 99.9% There is 0.0% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Invesco Biotechnology & Genome ETF has 0.1% of the portfolio in cash.
Assets Under Management
The fund has $277 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
PBE Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Invesco Biotechnology & Genome ETF expense ratio is average compared to funds in the Health category. Invesco Biotechnology & Genome ETF has an expense ratio of 0.58%, which is 12% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Invesco Biotechnology & Genome ETF has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 40% for the Health category.
Recently, in the month of June 2026, Invesco Biotechnology & Genome ETF returned 8.0%, which earned it a grade of C, as the Health category had an average return of 8.7%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Invesco Biotechnology & Genome ETF has a trailing yield of 1.73%, which is above the 1.12% category average.
The fund normally distributes its income quarterly and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Invesco Biotechnology & Genome ETF Grades
Year to date, the ETF has returned 10.4%, 0.2 percentage points better than the category, which translates into a grade of C. The fund has returned 42.5% over the past year (grade of B), 14.4% over the past three years (grade of B) and 3.4% per year over the past five years (grade of C) and 9.6% per year over the past 10 years (grade of C).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Invesco Biotechnology & Genome ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
PBE Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| PBE Return (NAV) | 8.0% | 14.2% | 42.5% | 14.4% | 3.4% | 9.6% |
| PBE Return (Price) | 8.0% | 14.3% | 42.5% | 14.4% | 3.5% | 9.6% |
| NAV +/- Price Return | -0.019% | -0.084% | -0.063% | 0.017% | -0.010% | -0.012% |
| Health Avg | 8.7% | 13.9% | 37.6% | 10.6% | 1.5% | 9.5% |
| PBE Grade (NAV) | C | C | B | B | C | C |
| +/- Category (NAV) | -0.7% | 0.3% | 4.9% | 3.8% | 1.9% | 0.1% |
| PBE Tax-Cost Ratio | na | na | 0.8% | 0.3% | 0.2% | 0.1% |
PBE Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| PBE Return (NAV) | 10.4% | 24.7% | 1.1% | 3.7% | -10.8% | 1.6% | 25.5% | 18.2% | 0.2% | 22.4% | -23.0% |
| PBE Return (Price) | 10.3% | 24.8% | 1.1% | 3.7% | -10.8% | 1.5% | 25.7% | 18.7% | -0.2% | 22.3% | -22.9% |
| NAV +/- Price Ret | -0.007% | 0.006% | -0.002% | 0.011% | 0.006% | -0.008% | 0.006% | 2.2% | -179.1% | -0.7% | -0.5% |
| Health Avg | 10.1% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| PBE Grade (NAV) | C | B | C | B | C | D | B | F | C | C | F |
| +/- Category | 0.2% | 2.9% | 1.0% | 1.5% | 5.5% | -2.7% | -5.0% | -7.1% | 1.7% | -4.0% | -12.8% |
| Risk Measures | |
| Beta: | 0.79 |
| R-Squared: | 33% |
| Standard Deviation: | 17.3% |
| Category Risk Index: | 0.87 |
| Category Risk Rating: | Average |
| Total Risk Index: | 1.43 |
| Total Risk Rating: | Above Average |
| Portfolio Characteristics | |
| Yield: | 1.7% |
| Total Assets: | $ 278 Mil |
| Share Class Assets: | $ 278 Mil |
| Turnover: | na |
| Expense Ratio: | 0.58% |
| Index Fund: | Yes |
| Index Tracked: | S&P 500 (TR) (1970) |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Quarterly |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 19.1 years | |||
| Average Tenure: 14.3 years | |||
| Managers (Year): Hubbard Peter (2007), Jeanette Michael (2008), Doshi Pratik (2020) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 32 |
| % in Top 10 Holdings: | 44.5% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 0.0% |
Portfolio Allocation |
|
| Domestic Stock: | 99.9% |
| Foreign Stock: | 0.0% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Invesco |
| Phone Number: | 800-983-0903 |
| Website: | www.invescopowershares.com |
| Inception Date: | June 23, 2005 |
Expenses and Fees
| Expense Ratio (%): | 0.58% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.52% |
